Cup-With-Handle Base: Common, Not Always Simple

Cup-with-handle bases are common. They launch many of the most successful stock runs. But practiced investors know not to confuse "familiar" with "simple."

The cup-with-handle pattern can be cagey, challenging investors with difficult choices. This is why it's worth studying and understanding the nuances found in recent examples to see what is working and what is not.

Regeneron Pharmaceuticals (REGN) launched out of a cup in December 2009. The base was V-shaped, a flaw (please see a historical chart on MarketSmith.com). In addition, IBD-style investors would have likely sat out the breakout because the drugmaker wasn't set to become profitable until the first quarter of 2012.

It wasn't until after the company's second profitable quarter, reported in July last year, that the stock staged its real breakout — also from a cup with handle.

The key prerequisite was in place: a steep climb of more than 30% before the pattern started to form in April. Some investors may have been reading the pattern as a double-bottom base with a 137.92 buy point. But the first pullback appears too shallow, and the stock didn't rebound quickly after hitting a low of 107.31 in late June. (1)

The stock shot up near 137 in heavy trade on July 25, the day the company reported earnings. It gained 5% in strong trade the following day, but still hung below the pivot.

When shares finally did clear the mark, it was in very weak trade — clearly not a breakout. The stock traded sideways and closed tight for four weeks. In the process, it formed a handle with a 142.06 buy point.

Rumors of a takeover by French drugmaker Sanofi (SNY) sent shares up 3% on Aug. 23. The strong volume move broke shares above the buy point, christening an advance that has tallied a 119% gain through last week.

When Actavis (ACT) finished a cup-with-handle base in September 2011, investors may have been leery. The stock had just cleared a second-stage cup with handle, but only briefly, before diving into the much deeper base. The correction undercut the prior base and reset the stock's base count. That was a positive. But the cup's right side was not picture perfect.

First, it erupted practically straight up from the bottom in an 11% gain, to retake both 10- and 40-week-lines support in the week ended March 23, 2012. Then it began to form a handle with an upward drift, a negative. This weighed two flaws against the pattern.

But by early April, it had a mild shakeout, setting up a 67.71 buy point. On April 20, it cleared that buy point on a barely sufficient 38% increase in volume, then wavered for a few sessions.

On April 26, a 7% stab higher in huge volume sealed the breakout. It also set in motion a run-up that had doubled the stock's price through Friday's close.

Cup-with-handle bases are common. They launch many of the most successful stock runs. But practiced investors know not to confuse "familiar" with "simple."

The cup-with-handle pattern can be cagey, challenging investors with difficult choices. This is why it's worth studying and understanding the nuances found in recent examples to see what is working and what is not.

Regeneron Pharmaceuticals (REGN) launched out of a cup in December 2009. The base was V-shaped, a flaw (please see a historical chart on MarketSmith.com). In addition, IBD-style investors would have likely sat out the breakout because the drugmaker wasn't set to become profitable until the first quarter of 2012.

It wasn't until after the company's second profitable quarter, reported in July last year, that the stock staged its real breakout — also from a cup with handle.

The key prerequisite was in place: a steep climb of more than 30% before the pattern started to form in April. Some investors may have been reading the pattern as a double-bottom base with a 137.92 buy point. But the first pullback appears too shallow, and the stock didn't rebound quickly after hitting a low of 107.31 in late June. (1)

The stock shot up near 137 in heavy trade on July 25, the day the company reported earnings. It gained 5% in strong trade the following day, but still hung below the pivot.

When shares finally did clear the mark, it was in very weak trade — clearly not a breakout. The stock traded sideways and closed tight for four weeks. In the process, it formed a handle with a 142.06 buy point.

Rumors of a takeover by French drugmaker Sanofi (SNY) sent shares up 3% on Aug. 23. The strong volume move broke shares above the buy point, christening an advance that has tallied a 119% gain through last week.

When Actavis (ACT) finished a cup-with-handle base in September 2011, investors may have been leery. The stock had just cleared a second-stage cup with handle, but only briefly, before diving into the much deeper base. The correction undercut the prior base and reset the stock's base count. That was a positive. But the cup's right side was not picture perfect.

First, it erupted practically straight up from the bottom in an 11% gain, to retake both 10- and 40-week-lines support in the week ended March 23, 2012. Then it began to form a handle with an upward drift, a negative. This weighed two flaws against the pattern.

But by early April, it had a mild shakeout, setting up a 67.71 buy point. On April 20, it cleared that buy point on a barely sufficient 38% increase in volume, then wavered for a few sessions.

On April 26, a 7% stab higher in huge volume sealed the breakout. It also set in motion a run-up that had doubled the stock's price through Friday's close.

See Also

The Ireland-based drugmaker and marketing partner Medicines360 won FDA approval for a hormonal contraceptive device for women. The intrauterine device, called Liletta, releases a hormone to inhibit thickening of the womb lining, which prevents pregnancy. The companies expect it to be available in ...

Investors should look from A to Z to find the very best stocks. But right now, you can find several A-grade companies near the start of the list.IBD's Rising Estimates Screen of the Day looks for top-rated stocks on which analysts have been raising earnings estimates. Rising EPS views signal ...

Pharmacyclics (NASDAQ:PCYC) stock soared to an all-time high Wednesday on media reports that the biotech is considering selling itself to a big pharmaceuticals company. Pharmacyclics, whose only marketed product is the Imbruvica blood-cancer drug, has drawn interest from Johnson & Johnson ...

There is nothing like scanning through scores of charts to make you appreciate the rarity of a nicely formed base. One of the traits that make such pieces of work stand out is symmetry. Bases happen all the time. And usually they look like what they are: random patterns formed by the combined ...

Generic-drug maker Lannett Co. in recent quarters has surged on price increases and, more recently, volume gains on key prescription medications. Like some other drug companies in the news this week, Lannett (NYSE:LCI) is on the hunt for potential acquisitions that could help expand its offerings, ...

02/24/2015 03:58 PM ET

More Investor's Corner Articles:

A stock chart never lies. Sometimes, however, the chart will mumble. Catching the chart's drift can be difficult under those circumstances. That's why the investor needs every chart-reading tool available. One key tool for stock chart analysis is the 10-week moving average line. As the individual ...

IBD readers will find many references to volume in market columns. Why? "Volume is your best measure of supply and demand and institutional sponsorship — two vital ingredients in successful stock analysis," IBD founder and Chairman William O'Neil wrote in "How to Make Money in Stocks." "Learn ...

Many investors are drawn to low-priced stocks like bears to honey. Truth is, it's an area of the market where institutional investors rarely fish. That means you shouldn't fish there, either. Prior to today, seven columns in this space have addressed the question: What makes a great base? Today's ...

A winning stock will typically advance in a predictable way. It rises from a first-stage base, moves higher, then builds subsequent bases, each one higher than the previous, until it finally tops. It doesn't take rocket science to understand that the breakout from a first-stage base in a new bull ...

For many successful stocks, a base's handle is the final preparation for a breakout. It's one of the last chances for a stock to make a good impression. So study it carefully. Why? The handle not only shapes the end of the base, it also sets the buy point and sways the chances of success or ...

Select market data is provided by Interactive Data Corp. Real Time Services. Price and Volume data is delayed 20 minutes unless otherwise noted, is believed accurate but is not warranted or guaranteed by Interactive Data Corp. Real Time Services and is subject to Interactive Data Corp. Real Time Services terms. All times are Eastern United States. *Reflects real-time index prices.